pharma · Advanced Systemic Mastocytosis · Systemic Mastocytosis
Blueprint Medicines
Blueprint Medicines (Netherlands) B.V.
Blueprint Medicines (Netherlands) is a pharma organization headquartered in EU. Primary therapeutic focus areas include Advanced Systemic Mastocytosis, Systemic Mastocytosis, GIST, Indolent Systemic Mastocytosis, Indolen
Cambridge, USA HQ
2011 Founded
741 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Founded
- 2011
- Employees
- 741
- Programs
- 8
- Drugs
- 9
- Patents
- 0
Avapritinib, Avapritinib
Approved · small molecule · Systemic Mastocytosis
Avapritinib, Avapritinib for Systemic Mastocytosis is a Approved program (small_molecule) at Blueprint Medicines (Netherlands) B.V. with 1 ClinicalTrials.gov record(s).
Internal code BLU-285-2404
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Blueprint Medicines (Netherlands) B.V.
- Phase
- Approved
- Modality
- small_molecule
- Indication
- Systemic Mastocytosis
- Status
- active
- Trials
- 1